Evidence map›Paper›PMID 41295207›Full record

ReviewJournal of personalized medicine2025

Impact of Complex Genetic and Drug-Drug Interactions on Tamoxifen Metabolism and Efficacy.

Ibtissam Saad, Kaoutar Bentayebi, Soukaina Ettoury, Oumaima Zarrik, Ilhame Bourais, Saber Boutayeb, Caroline Samer, Youssef Daali, Rachid Eljaoudi, Sara Louati

Abstract readReview
In one paragraph

Review in Journal of personalized medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ibtissam SaadResearch Laboratory in Drug Sciences, Mohammed VI Faculty of Pharmacy, Mohammed VI University of Sciences and Health (UM6SS), Casablanca 20100, Morocco.ORCID 0009-0007-5478-2123
Kaoutar BentayebiMedical Biotechnology Laboratory, Medical and Pharmacy School, Mohammed V University, Rabat 10000, Morocco.
Soukaina EttouryMedical Biotechnology Laboratory, Medical and Pharmacy School, Mohammed V University, Rabat 10000, Morocco.ORCID 0000-0003-1650-8661
Oumaima ZarrikMedical Biotechnology Laboratory, Medical and Pharmacy School, Mohammed V University, Rabat 10000, Morocco.ORCID 0000-0003-1979-5109
Ilhame BouraisResearch Laboratory in Drug Sciences, Mohammed VI Faculty of Pharmacy, Mohammed VI University of Sciences and Health (UM6SS), Casablanca 20100, Morocco.ORCID 0000-0002-4995-7837
Saber BoutayebMohammed VI Center for Research and Innovation (CM6RI), Rabat 10112, Morocco.
Caroline SamerFaculty of Medicine, University of Geneva, 1205 Geneva, Switzerland.
Youssef DaaliFaculty of Medicine, University of Geneva, 1205 Geneva, Switzerland.ORCID 0000-0002-8391-9383
Rachid EljaoudiResearch Laboratory in Drug Sciences, Mohammed VI Faculty of Pharmacy, Mohammed VI University of Sciences and Health (UM6SS), Casablanca 20100, Morocco.ORCID 0000-0002-0692-2036
Sara LouatiMedical Biotechnology Laboratory, Medical and Pharmacy School, Mohammed V University, Rabat 10000, Morocco.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tamoxifen remains the standard treatment for hormone-sensitive breast cancer. However, significant interindividual variability in treatment response is observed. This variability may be partially explained by differences in the biotransformation of tamoxifen, a prodrug, into its active metabolites. To address this, we conducted a comprehensive literature search across several databases to examine current evidence on single-gene and multi-gene variations throughout the metabolic and transport pathways of tamoxifen and their impact on pharmacokinetics and clinical efficacy. We also explore the influence of drug-drug-gene interactions and review clinical strategies currently employed to manage treatment variability. Overall, growing evidence highlights the influence of pharmacogenetic variability, particularly

Indexed as

breast cancerpharmacogeneticsprecision medicinetamoxifentamoxifen metabolism

Identifiers

PMID41295207
PMCPMC12653777

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.